These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24122209)

  • 1. Mouse tumour models to guide drug development and identify resistance mechanisms.
    Das Thakur M; Pryer NK; Singh M
    J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mighty mouse: genetically engineered mouse models in cancer drug development.
    Sharpless NE; Depinho RA
    Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From mice to men: GEMMs as trial patients for new NSCLC therapies.
    Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
    Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of selecting the 'right' in vivo oncology pharmacology model.
    Firestone B
    Curr Opin Pharmacol; 2010 Aug; 10(4):391-6. PubMed ID: 20634135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New models for cancer research: human cancer stem cell xenografts.
    Baiocchi M; Biffoni M; Ricci-Vitiani L; Pilozzi E; De Maria R
    Curr Opin Pharmacol; 2010 Aug; 10(4):380-4. PubMed ID: 20561817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs.
    Magni P; Terranova N; Del Bene F; Germani M; De Nicolao G
    IEEE Trans Biomed Eng; 2012 Aug; 59(8):2161-70. PubMed ID: 22575633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Pharmacology Models for Cancer Target Research.
    Chen D; An X; Ouyang X; Cai J; Zhou D; Li QX
    Methods Mol Biol; 2019; 1953():183-211. PubMed ID: 30912023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived tumour xenografts as models for breast cancer drug development.
    Marangoni E; Poupon MF
    Curr Opin Oncol; 2014 Nov; 26(6):556-61. PubMed ID: 25188472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
    Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
    Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling therapy resistance in genetically engineered mouse cancer models.
    Rottenberg S; Jonkers J
    Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mathematical model to study the effects of drugs administration on tumor growth dynamics.
    Magni P; Simeoni M; Poggesi I; Rocchetti M; De Nicolao G
    Math Biosci; 2006 Apr; 200(2):127-51. PubMed ID: 16516246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
    Mazur PK; Siveke JT
    Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.
    Wartha K; Herting F; Hasmann M
    Pharmacol Ther; 2014 Jun; 142(3):351-61. PubMed ID: 24412280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.
    Rosfjord E; Lucas J; Li G; Gerber HP
    Biochem Pharmacol; 2014 Sep; 91(2):135-43. PubMed ID: 24950467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design.
    Hadjiandreou MM; Mitsis GD
    IEEE Trans Biomed Eng; 2014 Feb; 61(2):415-25. PubMed ID: 24021634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.
    Frederiksen LJ; Sullivan R; Maxwell LR; Macdonald-Goodfellow SK; Adams MA; Bennett BM; Siemens DR; Graham CH
    Clin Cancer Res; 2007 Apr; 13(7):2199-206. PubMed ID: 17404104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.